Meeting
2020 Genitourinary Cancers Symposium
Trends in PRO reporting in clinical trials leading to GU cancer drug approvals from 2007 to 2018.
Authors
Monica Tamil
The University of Texas Health Science Center at Houston, Houston, TX
Monica Tamil , Houssein Safa , Adele Semaan , Jad Chahoud
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Renal Cell Cancer
Track
Renal Cell Cancer
Sub Track
Patient-Reported Outcomes and Real-World Evidence
Citation
J Clin Oncol 38, 2020 (suppl 6; abstr 641)
Abstract #
641
Poster Bd #
E5
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
The inclusion of health-related quality of life and other patient-reported outcomes in landmark trials for Food and Drug Administration oncology drug approvals: An analysis of cancer drug approvals between 2006 and 2022.
First Author: Ademola Samuel Ojo
Poster
2020 ASCO-SITC Clinical Immuno-Oncology Symposium
Trends in PRO reporting in clinical trials leading to cancer immunotherapy drug approvals from 2011 to 2019.
First Author: Houssein Safa
Poster
2023 ASCO Quality Care Symposium
Patient-reported outcomes and financial toxicity in head and neck cancer (PaRTNer): Longitudinal assessment of financial toxicity and associated quality of life from a pilot study.
First Author: Pooja Karukonda
Poster
2023 ASCO Breakthrough
Disparities in African-American patient enrollment in pivotal phase 3 immunotherapy trials that led to FDA drug approval in patients with non-small cell lung cancer.
First Author: Chimezie Ubbaonu